期刊文献+

BRMS1、HDAC1、VEGF-C在乳腺癌组织中的表达及意义 被引量:4

Expression and Significance of BRMS1,HDAC1 and VEGF-C in Breast Cancer
暂未订购
导出
摘要 目的探讨BRMS1、HDAC1及VEGF-C蛋白在乳腺癌、乳房纤维瘤及正常乳腺组织的表达及意义。方法采用免疫组织化学方法随机检测60例乳腺癌组织标本BRMS1、HDAC1、VEGF-C蛋白的表达,随机收集乳房纤维瘤组织及其旁正常乳腺组织各20例作为对照组,结合临床病理资料分析其临床意义。结果BRMS1在乳腺癌组织中表达率为60%,在乳房纤维瘤组织中表达率为85%,在正常乳腺组织中表达率为95%,乳腺癌组织中的BRMS1的表达明显低于乳房纤维瘤和正常乳腺组织(P<0.05)。HDAC1在乳腺癌组织中表达率为91.7%,在乳房纤维瘤组织中表达率为55%,在正常乳腺组织中表达45%,HDAC1在乳腺癌组织中的表达明显高于乳房纤维瘤和正常乳腺组织(P<0.01),乳腺癌中VEGF-C的表达58.3%高于乳房纤维瘤25%和正常组织20%(P<0.05)。结论BRMS1、HDAC1和VEGF-C共同参与了乳腺癌的转移,联合检测BRMS1、HDAC1及VEGF-C的表达有助于判断其预后。 Objective To investigate the expression and clinical significance of breast cancer metastasis suppressor 1 (BRMS1)protein, histone deacetylase 1 (HDAC1) and vascular endothelial cell growth factor-C (VEGF-C) protein in breast cancer. Methods The expression of BRMS1 protein,HDAC1 and VEGF-C was detected by using immunohistochemical technique in 60 cases of breast cancer,20 cases of breast fibroids and 20 cases of adjacent normal breast tissue as control and the clinical significance was analyzed with histopalthological records. Results The positive rate of BRMS1 expression was 60% in breast cancer tissue,85% in breast fibroids and 95% in normal breast tissue,show- ing the positive rate of BRMSI in breast cancer was much lower than that in breast fibroids and normal breast tissue(P〈O.05). The positive rate of HDAC1 expression was 91.7% in breast cancer,55% breast fibroids and 45% in normal breast tissue,showing the positive rate of HDAC1 in breast cancer was obviously higher than that in breast fibroids and normal breast tissue(P〈0.01 ). The positive rate of VEGF-C expression was 58.3% in breast cancer, 25% in breast fibroids and 20% in normal breast tissue(P〈0.05). Conclusion BRMS1, HDAC1 and VEGF-C might synergistically promote the metastasis of breast cancer. Therefore,the combined detection of the expression of BRMS1 HDAC 1 and VEGF-C may be helpful in the determination of the prognosis of breast cancer.
作者 夏根玉 陈斌
出处 《中国现代医生》 2010年第9期10-12,共3页 China Modern Doctor
关键词 BRMS1 HDAC1 VEGF—C 乳腺癌 免疫组织化学 BRMS1 HDAC1 VEGF-C Breast cancer Immunohistochemistry
  • 相关文献

参考文献10

  • 1Kurose K,Gilley K,Matsumoto S,et al. Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas[J]. Nat Genet,2002,32(3) :355-357.
  • 2李治,帅晓明,黄韬.MMP-2、MMP-9在乳腺癌转移中作用的研究[J].华西医学,2006,21(1):43-44. 被引量:17
  • 3Samant RS,Seraj MJ,Saunders MM,et al. Analysis of mechanisms underlying BRMS1 suppression of metastasis[J]. Clin Exp Metastasis,2000, 18(8) :683-693.
  • 4DeWald DB,Torabinejad J,Samant RS,et al. Metastasis suppression by breast cancer metastasis suppressor 1 involves reduction of phosphoinositide signaling in MDA-MB-435 breast carcinoma cells[J]. Cancer Res, 2005,65(3):713-717.
  • 5Hedley BD,Welch DR,Allan AL,et al. Downregulation of osteopont in contributes to metastasis suppression by breast cancer metastasis suppressor 1[J]. Int J Cancer, 2008,123(3) :526-534.
  • 6Yang L,Mei Q,Zielinska-Kwiatkowska A,et al. An ERG (ets-related gene)-associated histone methyltransferase interacts with histone deacety- lases 1/2 and transcription corepressors mSin3A/B[J]. Biochem J,2003, 369(Pt 3):651-657.
  • 7Kawai H,Li H,Avraham S,et al. Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor alpha[J]. Int J Cancer, 2003,107(3 ) : 353-358.
  • 8Zhou Q,Agoston AT,Atadja P,et al. Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells[J]. Mol Cancer Res,2008,6 (5) : 873-83.
  • 9Saharinen P,Tammela T,Karkkainen MJ,et al. Lymphatic vaseulature: development,molecular regulation and role in tumor metastasis and inflammation[J]. Trends I mmunol, 2004,25 (7) : 387-395.
  • 10Benest AV, Harper S J, Herttuala SY, et al. VEGF-C induced angiogenesis preferentially occurs at a distance from lymphangiogenesis[J]. Cardiovasc Res,2008,78(2) : 315-323.

二级参考文献9

  • 1Yu Q,Stamenkovic I.Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis[J].Genes,2000,14(2):163-76.
  • 2Lhotak S,Elavathil LJ,Vukmirovic-Popovic,et al.Immunolocalization of matrix-metalloproteinases and their inhibitors in clinical specimens of bone metastasis from breast carcinoma[J].Clin Exp Metastasis,2000,18(6):463-70.
  • 3Lee PP,Hwang JJ,Murphu G,et al.Functional significance of MMP-9 in tumor necrosis factor-induced proliferation and branching morphogenesis of mammary epithelial cells[J].Endocrinology,2000,141(10):3764-73.
  • 4Canning MT,Postovit LM,Clarke SH,et al.Oxygen-mediated regulation of gelatinase and tissue inhibitor of metalloproteinases-1 expression by invasive cells[J].Exp Cell Res,2001,267(1):88-94.
  • 5Care A,Felicetti F,Meccia E,et al.HOXB7:a key factor for tumor-associated angiogenic switch[J].Cancer Res,2001,61(17):6532-9.
  • 6Kondo S,Kubota S,Shimo T,et al.Connective tissue growth factor increased by hypoxia may initiate angiogenesis in collaboration with matrix metalloproteinases[J].Carcinogenesis,2002,23(5):769-76.
  • 7Pacheco MM,Nishimoto IN,Mourao Neto M,et al.Prognostic significance of the combined expression of matrix metalloproteinase-9,urokinase type plasminogen activator and its receptor in breast cancer as measured by Northern blot analysis[J].Int J Biol Markers,2001,16(1):62-8.
  • 8Scorilas A,Karameris A,Arnogiannaki N,et al.Overexpression of matrix-metalloproteinase-9 in human breast cancer:a potential favourable indicator in node-negative patients[J].Br J Cancer,2001,84(11):1488-96.
  • 9Talvensaari-Mattila A,Paakko P.Turpeenniemi-Hujanen T;MMP-2 positivity and age less than 40 years increases the risk for recurrence in premenopausal patients with node-positive breast carcinoma[J].Breast Cancer Res Treat,1999,58(3):287-93.

共引文献16

同被引文献67

  • 1崔明,何雄斌,吴海燕.BRMS1蛋白在乳腺癌中的表达及临床意义[J].临床外科杂志,2009,17(11). 被引量:1
  • 2余德荣,游力,许晓群,李会庆,王郡甫,高春义.BRMS1 mRNA和CD44V6 mRNA在子宫内膜癌组织中的表达及意义[J].中华肿瘤防治杂志,2007,14(4):287-290. 被引量:16
  • 3霍志军,陈道瑾,李小荣,唐利立,刘鹏熙,吴唯.乳腺癌中HDAC1和ER的表达及意义[J].实用肿瘤杂志,2007,22(5):420-422. 被引量:4
  • 4Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future[J]. Nat Rev Drug Discov, 2006, 5(1) :37-50.
  • 5Mathers CD, Lonear D. Projections of ~obal mortality and burden of disease from 2002 to 2030 [J].PLoS Med, 2006,3 ( 11 ) : e442.
  • 6Allred DC, Harvey JM, Berardo M, et aZ. Prognostic and predictive factors in breast cancer by immunohistochemical analysis [ J ]. Mod Pathol, 1998,11(2) :155-168.
  • 7Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for hu- man epidermal growth factor receptor 2 testing in breast cancer: Ameri- can Society of Clinical Oncology/Cotlege of American Pathologists clin- ical practice guideline update [J].J Clin Oncol, 2013, 31(31) :3997-4013.
  • 8Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes dealing with the diversity of breast cancer:highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 [ J]. Ann Oncol,2011,22 : 1736-1747.
  • 9Park SY, Jun JA, Jeong KJ, et al. Histone deacetylases 1, 6 and 8 are critical for invasion in breast cancer[J]. Oncol Rep, 2011, 25 (6) :1677-1681.
  • 10Linares A, Dalenc F, Balaguer P, et al. Manipulating protein acetyla- tion in breast cancer:a promising approach in combination with hormo- nal therapies? [J]. J Biomed Biotechnol, 2011, 2011:856985.

引证文献4

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部